This Plain Language Summary of publication article (PLSP) from Future Oncology summarizes the latest results from the monarchE study, which involved participants with HR+, HER2-, node-positive, high-risk early breast cancer. The study compared outcomes between those who received abemaciclib with standard endocrine therapy after surgery and those who received endocrine therapy alone. It aimed to determine if abemaciclib reduced cancer recurrence compared to standard treatment alone.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial’ published in The Lancet Oncology.

This PLSP is based on an article called ‘Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study’ published in Annals of Oncology

Visit The Lancet using the link to read the original article.

Visit ESMO using the link to read the original article.